Quick Answer
A good tesamorelin dosage chart should not pretend that every reader needs the same number. It should separate three things: the current prescription-label dose, the clinical-trial dose used in the published evidence, and the research math needed to understand vial concentration.
The current EGRIFTA SV label lists 1.4 mg once daily. Major clinical studies with the older formulation commonly used 2 mg once daily. Research-vial math depends on vial size and liquid volume, so units should be calculated from concentration rather than copied from a generic chart.
Use the peptide calculatorCalculate concentration and syringe-unit math for research planning.Open calculatorLabel And Study Dosage Chart
Tesamorelin has unusually useful dosage context because there is both a current label and a published clinical-trial base. The chart below is for understanding source language, not for personal dosing.
| Source context | Tesamorelin dosage language | Why it matters |
|---|---|---|
| Current EGRIFTA SV label | 1.4 mg once daily, 0.35 mL after reconstitution. | Best source for current prescription-label dosing. |
| Older EGRIFTA study context | 2 mg subcutaneously once daily. | Major trial evidence used this daily structure. |
| DailyMed formulation note | 1.4 mg EGRIFTA SV exposure is similar to 2 mg older EGRIFTA exposure. | Explains why both numbers show up in credible sources. |
| Research peptide vial | 5 mg, 10 mg, or other total vial amounts. | A vial amount is not automatically a dose. |
Why Units Are Not Universal
Tesamorelin dosage in units depends on concentration. Concentration depends on how much peptide is in the vial and how much liquid is added. Change the liquid volume and the same syringe-unit mark represents a different amount.
That is why generic unit charts can mislead readers. A unit number that is correct for one vial and reconstitution volume can be wrong for another.
| Vial amount | Added liquid | Final concentration | What the chart tells you |
|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | Each 0.1 mL contains 0.5 mg. |
| 5 mg | 2 mL | 2.5 mg/mL | Each 0.1 mL contains 0.25 mg. |
| 10 mg | 1 mL | 10 mg/mL | Each 0.1 mL contains 1 mg. |
| 10 mg | 2 mL | 5 mg/mL | Each 0.1 mL contains 0.5 mg. |
These examples show why the math changes. They do not recommend a dose or protocol.
5 Mg Tesamorelin Dosage Questions
When readers ask about tesamorelin 5 mg dosage, they are usually asking about a vial size. A 5 mg vial can be reconstituted at different concentrations depending on liquid volume. The total amount in the vial remains 5 mg, but the amount represented by each syringe unit changes.
This is the key mental model: vial size tells you inventory. Concentration tells you measurement. A dosing protocol, if relevant, comes from a qualified clinical or research source.
10 Mg Tesamorelin Questions
Tesamorelin 10 mg searches are common because many research listings use 10 mg vial sizes. Again, the 10 mg number is usually the total amount in the vial. It does not mean 10 mg is a daily amount, a protocol, or a clinical recommendation.
For research planning, a 10 mg vial can be easier to calculate when the concentration is clearly defined. But it also makes mistakes easier if someone copies unit numbers from a different vial setup. Calculator inputs should match the actual vial and liquid volume.
What A Responsible Tesamorelin Protocol Discussion Includes
A responsible tesamorelin protocol discussion starts with source context. The current label says one thing. Older trials used another formulation and dose. Research products introduce a separate measurement problem. Collapsing those into one quick answer is how bad dosage content gets written.
The better structure is:
| Question | Better answer |
|---|---|
| What does the label say? | EGRIFTA SV lists 1.4 mg once daily. |
| What did major trials study? | Older-formulation studies commonly used 2 mg once daily. |
| What does the vial contain? | The total peptide amount, such as 5 mg or 10 mg. |
| How many units is that? | It depends on final concentration after reconstitution. |
Why Listing Clarity Matters
Dosage math assumes the vial contains what the listing says it contains. That makes listing clarity important before any unit chart is useful: vial amount, compound name, COA signal, and whether the product is a single peptide or a blend.
Tesamorelin Vendors With COA Signals
View all Tesamorelin vendors| Vendor | Country | COAs | Rating | Reviews | Notes | Website |
|---|---|---|---|---|---|---|
| LA Peptides | USA | Yes | 5.0 | 1 | Verified listing | Buy |
| NextGenPeps | USA | Yes | 5.0 | 1 | Verified listing | Buy |
| Alpha Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| Ascension Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| BioCollex | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| Coastal Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
FAQ
What is the best tesamorelin dosage chart?
The best chart separates label dosing, clinical-study dosing, vial size, liquid volume, concentration, and syringe units.
How do I calculate tesamorelin dosage in units?
Use the vial amount and liquid volume to calculate concentration first. Then convert the target amount into syringe volume or units.
Is tesamorelin 10 mg common?
Tesamorelin 10 mg is common as a research-vial size, but vial size should not be confused with a clinical dose.
Why does EGRIFTA SV say 1.4 mg when studies used 2 mg?
The current SV formulation is different from the older study formulation, and DailyMed states that exposure is similar between the 1.4 mg SV dose and the older 2 mg EGRIFTA dose.